Clinical Trial Update: PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PLX038 for metastatic platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PLX038

Snippet

Sponsor: Mayo Clinic | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: RECRUITING